
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics is a promising company due to their advanced drug pipeline focused on targeting specific genetic abnormalities through their proprietary platform. The success of FHD-909 in clinical trials and partnership with Eli Lilly bodes well for their potential success in the market. However, there is still uncertainty about the efficacy and commercialization of their drugs, and the company will need to continue to develop and prove the effectiveness of their targeted therapies.
Bears say
Foghorn Therapeutics is a relatively new company in the biotechnology industry and is still in its early stages as a clinical-stage precision therapeutics company. However, the recent discontinuation of its flagship program FHD-286 in early phase clinical trials for two different types of cancer and the lack of any current drug candidates in its pipeline raise concerns about the company's potential for success in the future. Additionally, the dependence on regulatory approvals for its treatments and the high development costs associated with this industry further add to the risk of investing in Foghorn Therapeutics's stock.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares